Elvanse (lisdexamfetamine) and Amfexa (dexamfetamine) drug interactions to watch for
Elvanse and Amfexa are both amphetamine stimulants and share key interaction risks. The most important interactions to avoid are monoamine oxidase inhibitors (MAOIs) and combinations that increase serotonin syndrome risk or amphetamine exposure. [1]
MAOI interactions (hypertensive crisis risk)
- MAOIs (non-selective, irreversible) are contraindicated with dexamfetamine and are associated with possible hypertensive crisis. (medicines.org.uk)
- MAOIs with lisdexamfetamine are contraindicated during or within 14 days after MAOI use because of risk of hypertensive crisis. [2]
- Examples often encountered in this category include linezolid and intravenous methylene blue (listed in lisdexamfetamine labeling context as MAOI-like risks). [2]
Serotonergic drug interactions (serotonin syndrome risk)
- Concomitant serotonergic drugs with lisdexamfetamine increase the risk of serotonin syndrome. [1]
- Lisdexamfetamine labeling lists multiple serotonergic medication categories to watch, including SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John’s Wort, and others. [1]
- Lisdexamfetamine labeling instructs that if the combination is clinically warranted, initiation should be at lower doses and patients should be monitored closely for serotonin syndrome during initiation or dose increase. [1]
CYP2D6 inhibitor interactions (increased stimulant exposure)
- CYP2D6 inhibitors can increase exposure to dextroamphetamine (the active metabolite of lisdexamfetamine) and increase serotonin syndrome risk with lisdexamfetamine. [1]
- When the combination is used with lisdexamfetamine, labeling recommends lower starting doses and close monitoring for serotonin syndrome during initiation and after dose increases. [1]
Urine pH–altering interactions (pharmacokinetic effects)
- Urinary alkalinizing agents should be avoided with lisdexamfetamine because they can increase blood levels and potentiate amphetamine effects. [1]
- Urinary acidifying agents can lower blood levels and efficacy of amphetamines. [1]
- For dexamfetamine (Amfexa), labeling specifies:
- Urinary acidifying agents (examples: ammonium chloride, sodium acid phosphate) increase urinary excretion and can lower blood levels. (medicines.org.uk)
- Urinary alkalinizing agents (examples: acetazolamide, some thiazides) can decrease urinary excretion and increase blood levels. (medicines.org.uk)
Cardiovascular and antihypertensive interactions (BP/HR effects)
- Lisdexamfetamine labeling highlights increased blood pressure and heart rate as key risks to monitor during treatment. [1]
- Dexamfetamine labeling notes potential reduction of antihypertensive effects:
- Dexamfetamine may inhibit the antihypertensive action of guanethidine or clonidine. (medicines.org.uk)
-
Beta-blockers may lead to severe hypertonia because therapeutic action may be inhibited by dexamfetamine. (medicines.org.uk)
-
Dexamfetamine labeling also advises caution with vasopressors due to possible increased blood pressure effects. (medicines.org.uk)
- Lisdexamfetamine labeling includes alkalinizing agent avoidance and general monitoring for BP/HR effects during amphetamine therapy. [1]
Tricyclic antidepressant interaction (cardiovascular potentiation)
- Lisdexamfetamine labeling states that tricyclic antidepressants may enhance cardiovascular effects and increase central amphetamine concentration. [1]
- Lisdexamfetamine labeling recommends frequent monitoring and dose adjustment or alternative therapy based on clinical response when tricyclic antidepressants are used concomitantly. [1]
Practical “red flag” combination checklist
- MAOI within the contraindicated window (for lisdexamfetamine: during or within 14 days) should trigger avoidance. [1]
- Any serotonergic regimen (including common antidepressant and pain/antimigraine classes listed in lisdexamfetamine labeling) should trigger heightened monitoring for serotonin syndrome. [1]
- Strong CYP2D6 inhibitors should trigger increased serotonin syndrome risk monitoring with lisdexamfetamine. [1]
- Urinary alkalinizers vs acidifiers should be reviewed because they can meaningfully change amphetamine blood levels and effect. [1]